A novel pathway to the manifestations of metabolic syndrome

Obesity Research

Volumn 12, Issue 2, 2004, Pages 180-186

  Sonnenberg, Gabriele E ^a,b   Krakower, Glenn R ^a   Kissebah, Ahmed H ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adiponectin; NF B; Oxidative stress; TNF

Indexed keywords

ADIPONECTIN; CELL ADHESION MOLECULE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; HUMAN; METABOLIC SYNDROME X; METABOLISM; OBESITY; OXIDATIVE STRESS; PHYSIOLOGY; REVIEW;

ADIPONECTIN; ADIPOSE TISSUE; CELL ADHESION MOLECULES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; METABOLIC SYNDROME X; NF-KAPPA B; OBESITY; OXIDATIVE STRESS; PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2942698938     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2004.24     Document Type: Review

References (100)

1. Frühbeck G, Gómez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol. 2001;280:E827-47.
2. Stephens JM, Pekala PH. Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha: regulation is coordinate and independent of protein synthesis. J Biol Chem. 1992;267:13580-4.
3. Banks RE, Forbes MA, Storr M, et al. The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol. 1995;102:217-23.
4. Grunfeld C, Zhao C, Fuller J, et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest. 1996;97:2152-7.
5. Bulló M, García-Lorda P, Megias I, Salas-Salvadó J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res. 2003;11:525-31.
6. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 1993;259:665-8.
7. Moller DE. Potential role of TNFα in the pathogenesis of insulin resistance and type 2 diabetes. Trend Endocrinol Metab. 2000;11:212-7.
8. Hauner H, Petruschke T, Russ M, Röhrig K, Eckel J. Effects of tumour necrosis factor alpha (TNFα) on glucose transport and lipid metabolism of newly differentiated human fat cells in cell culture. Diabetologia. 1995;38:764-71.
9. Zinman B, Hanley AJG, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-α concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab. 1999;84:2172-8.
10. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord. 1998;22:1145-58.
11. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol. 1998;55:1139-49.
12. Porter MH, Cutchins A, Fine JB, Bai Y, DiGirolamo M. Effects of TNF-α on glucose metabolism and lipolysis in adipose tissue and isolated fat-cell preparations. J Lab Clin Med. 2002;139:140-6.
13. Wabitsch M, Hauner H, Heinze E, Teller WM. The role of growth hormone/insulin growth factors in adipocyte differentation. Metabolism. 1995;44:45-9.
14. Kras KM, Hausman DB, Martin RJ. Tumor necrosis factor-α stimulates cell proliferation in adipose tissue-derived stromal-vascular cell culture: promotion of adipose tissue expansion by paracrine growth factors. Obes Res. 2000;8:186-93.
15. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271:665-8.
16. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79-83.
17. Yang W-S, Lee W-J, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001;86;3815-9.
18. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003;46:459-69.
19. Yokota T, Reddy Meka CS, Medina KL, et al. Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins. J Clin Invest. 2002;109:1303-10.
20. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930-5.
21. Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep. 2003;3:207-13.
22. Spranger J, Kroke A, Möhlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361:226-8.
23. Fruebis J, Tsao T-S, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A. 2001;98:2005-10.
24. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med. 2001;7:941-6.
25. Ma K, Cabrero A, Saha PK, et al. Increased β-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem. 2002;277:34658-61.
26. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care. 2002;25:971-6.
27. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002;87:2764-9.
28. Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci. 2002;103:137-42.
29. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients whith essential hypertension. Am J Hypertens. 2003;16:72-5.
30. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473-6.
31. Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002;105:2893-8.
32. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002;277:25863-6.
33. Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in presenting vascular stenosis. The missing link of adipovascular axis. J Biol Chem. 2002;277:37487-91.
34. Kappes A, Löffler G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res. 2000;32:548-54.
35. Maeda N, Takahashi M, Funahashi T, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094-9.
36. Grunfeld C, Feingold KR. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy. 1991;3:143-58.
37. Fasshauer M, Kralisch S, Klier M, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2003;301:1045-50.
38. Engeli S, Feldpausch M, Gorzelniak K, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes. 2003;52:942-7.
39. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000;102:1296-301.
40. Sun Z, Andersson R. NF-κB activation and inhibition: a review. Shock. 2002;18:99-106.
41. Okamato Y, Arita Y, Nishida M, et al. An adipoctye-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res. 2000;32:47-50.
42. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-43.
43. Weyer C, Yudkin JS, Stenhouwer CDA, Schalkwijk CG, Pratley RE, Tataranni PA. Hormonal markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis. 2002;161:233-42.
44. Collins T. Endothelial nuclear factor-κB and the initiation of the atherosclerotic lesion. Lab Invest. 1993;68:499-508.
45. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocrine Rev. 2002;23:599-622.
46. Azevedo-Martins AK, Lortz S, Lenzen S, Curi R, Eizirik DL, Tiedge M. Improvement of the mitochondrial antioxidant defense status prevents cytokine-induced nuclear factor-κB activation in insulin-producing cells. Diabetes. 2003;52:93-101.
47. de Koning EJP, Rabelink TJ. Endothelial function in the post-prandial state. Atherosclerosis. Suppl. 2002;3:11-6.
48. Nappo F, Esposito K, Cioffi M, et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol. 2002;39:1145-50.
49. Chen NG, Azhar S, Abbasi F, Carantoni M, Reaven GM. The relationship between plasma glucose and insulin responses to oral glucose, LDL oxidation, and soluble intercellular adhesion molecule-1 in healthy volunteers. Atherosclerosis. 2000;152:203-8.
50. Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2001;21:844-8.
51. Kondo A, Muranaka Y, Ohta I, et al. Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL. Clin Chem. 2001;47:893-900.
52. Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Intern Med. 2002;252:440-7.
53. de Nigris F, Lerman LO, Ignarro SW, et al. Beneficial effects of antioxidants and L-arginine on oxidation-sensitive gene expression and endothelial NO synthase activity at sites of disturbed shear stress. Proc Natl Acad Sci U S A. 2003;100:1420-5.
54. Matsunaga T, Hokari S, Koyama I, Harada T, Komoda T. NF-κB activation in endothelial cells treated with oxidized high-density lipoprotein. Biochem Biophys Res Commun. 2003;303:313-9.
55. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-7.
56. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest. 1996;97:2601-10.
57. Kowalska I, Straczkowski M, Szelachowska M, et al. Circulating E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in men with coronary artery disease assessed by angiography and disturbances of carbohydrate metabolism. Metabolism. 2002;51;733-6.
58. Parissis JT, Korovesis S, Giazitzoglou E, Kalivas P, Katritsis D. Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension. Correlations with plasma endothelin-1. Int J Cardiol. 2002;83:13-21.
59. Rajala U, Laakso M, Päivänsalo M, Pelkonen O, Suramo I, Keinänen-Kiukaanniemi S. Low insulin sensitivity measured by both quantitative insulin sensitivity check index and homeostasis model assessment method as a risk factor of increased intima-media thickness of the carotid artery. J Clin Endocrinol Metab. 2002;87:5092-7.
60. Schneider MP, Delles C, Fleischmann E, Schmidt BMW, John S, Schmieder RE. Effect of elevated triglyceride levels on endothelium-dependent vasodilation in patients with hypercholesterolemia. Am J Cardiol. 2003;91:482-4.
61. Tooke JE, Goh KL. Endotheliopathy precedes type 2 diabetes. Diabetes Care. 1998;21:2047-9.
62. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131-5.
63. Tamakoshi K, Yatsuja H, Kondo T, et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord. 2003;27:443-9.
64. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265:621-36.
65. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107:671-4.
66. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001;103:1194-7.
67. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-8.
68. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabelologia. 1990;33:306-10.
69. Kavazarakis E, Moutaki M, Gouriotis D, et al. The impact of serum lipid levels on circulating soluble adhesion molecules in childhood. Pediatr Res. 2002;52:454-8.
70. Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation. 2002;106:820-5.
71. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and β-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest. 2002;32(Suppl 3):24-34.
72. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology. 1992;130:43-52.
73. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNFα by human muscle. Relationship to insulin resistance. J Clin Invest. 1996;97:1111-6.
74. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40:1286-92.
75. Katsuki A, Sumida Y, Murashima S, et al. Serum levels of tumor necrosis factor-a are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1998;83:859-62.
76. Bolaffi JL, Rodd GG, Wang J, Grodsky GM. Interrelationship of changes in islet nicotine adenine dinucleotide, insulin secretion, and cell viability induced by interleukin-1 beta. Endocrinology. 1994;134:537-42.
77. Campbell IL, Oxbrow L, Harrison LC. Interferon-gamma: pleiotropic effects on a rat pancreatic beta cell line. Mol Cell Endocrinol. 1997;52:161-7.
78. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial function: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972-8.
79. Chan JCN, Cheung JCK, Stehouwer CDA, et al. The central roles of obesity-associated dyslipidemia, endothelial activation and cytokines in the Metabolic Syndrome - an analysis by structural equation modelling. Int J Obes Relat Metab Disord. 2002;26:994-1008.
80. Esposito K, Nicoletti G, Giugliano D. Obesity, cytokines and endothelial dysfunction: a link for the raised cardiovascular risk associated with visceral obesity. J Endocrinol Invest. 2002;25:646-9.
81. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care. 2002;5:551-9.
82. Lyon CJ, Law RE, Hsueh WA. Adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144:2195-200.
83. Kissebah AH, Sonnenberg GE, Myklebust J, et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci U S A. 2000;91:14478-83.
84. Comuzzie AG, Funahashi T, Sonnenberg G, et al. The genetic basis of plasma variation in adiponectin, a global endophenotype for obesity and the metabolic syndrome. J Clin Endocrinol Metab. 2001;86:4321-5.
85. Epinat JC, Gilmore TD. Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway. Oncogene. 1999;18:6896-909.
86. Yin M-J, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IkappaB kinase-beta. Nature. 1998;396:77-80.
87. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin inproves glucose metabolism in type 2 diabetes. J Clin Invest. 2002;109:1321-6.
88. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa-B activity through induction of I-kappa-B synthesis. Science. 1995;270:286-90.
89. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I-kappa-B-alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270:283-6.
90. Rossi A, Kapahi P, Natoli G, et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature. 2000;403:103-18.
91. Straus DS, Pascual G, Li M, et al. 15-deoxy-delta 12, 14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A. 2000;97:4844-9.
92. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterio Thromb Vasc Biol. 2003;23:85-9.
93. Yamauchi T, Kamon J, Waki H, et al. Gobular adiponectin protected ob/ob mice from diabetes and apoE-deficient mice from atherosclerosis. J Biol Chem. 2003;278:2461-8.
94. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology. 2002;143:998-1007.
95. Hirose H, Kawai T, Yamamoto Y, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism. 2002;51:314-7.
96. Duval C, Chinetti G, Trottein F, Fruchart J-C, Staels B. The role of PPARs in atherosclerosis. Trends Mol Med. 2002;8:422-30.
97. Schubert SY, Neeman I, Resnick N. A novel mechanism for the inhibition of NFκB activation in vascular endothelial cells by natural antioxidants. FASEB J. 2002;16:1931-3.
98. Milan G, Granzotto M, Scarda A, et al. Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss. Obes Res. 2002;10:1095-103.
99. Motoshima H, Wu X, Sinha MK, et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab. 2002;87:5662-7.
100. Hernández-Rodríguez J, Segarra M, Vilardell C, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis. Angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation. 2003;107:2428-34.